



Greenhillsbiotech.com

Contact : Joachim Seipelt
joachim.seipelt@meduniwien.ac.at

Green Hills Biotechnology Research Development and Trading GmbH (GHB) is a biopharmaceutical company based in Vienna, Austria. It was founded in 2002 and meanwhile has a staff of more than 30 employees. GHB uses its virological know-how to develop and commercialize innovative products that offer cost-effective treatment for a wide range of diseases.

The products developed by GHB are unique therapies against viral infectious diseases and cancer. In exploratory research and product development, GHB closely cooperates with national and international academic institutions and clinics, among them the Medical University Vienna, the Mount Sinai School of Medicine and the Institute for Medical Virology at Goethe University in Frankfurt/M.



Success Story of Green Hills Biotechnology



www.smesgolifesciences.org

EU FP Project : FLUVACC

Project Title: Live attenuated replication-defective influenza vaccine

Call details:

Priority : LSH
Submission date : 16.11.2004
Reference : LSH 2004-1.2.2-1

Project type:

- Integrated Project
- Network of Excellence
- Specific Targeted Research Project

Project Abstract:

The **FLUVACC** project is aimed at developing vaccines against pandemic influenza: Extensive know-how in virology, in particular in the field of interactions between viruses and host cells, enabled GHB to develop FluVacc, a live attenuated replication-defective influenza virus vaccine.

The EU decided to support this innovative technology by choosing it as a future strategy against different kinds of pandemic influenza. GHB and its international, highly renowned research partners in this project have continued to develop these vaccines based on a multidisciplinary approach involving such key steps as production, purification issues as well as clinical evaluations.

FLUVACC Consortium composition : 8 partners from 6 countries

<i>SME</i> Green Hills Biotechnology Research Development and Trade GmbH	AT
<i>SME</i> GPC Biotech AG	DE
<i>SME</i> BIA Separations d.o.o.	SI
<i>SME</i> BioTest s.r.o.	CZ

Institute of Influenza Russian Academy of Medical Sciences	RU
Medical University of Vienna	AT
Robert Koch Institute	DE
Weikom and Network	AT

Green Hills Biotechnology in FLUVACC

Green Hills Biotechnology's role in the Project is to develop the vaccine against influenza, by inducing immune response to the virus.



Intellectual Property Rights (IPR) are taken care of in the Consortium agreements.

SMEs go LifeSciences partner (FFG) provided a broad range of support and consultancy to GHB, in particular with regard to proposal submission as well as questions on project management and general administrative issues.

SMEs go LifeSciences partner :

FFG - www.ffg.at
Contact Person : Ms. Elli Tzatzani-Stepanovic - elli.stepanovic@ffg.at

SMEs go LifeSciences is co-funded by the European Commission

